Cost-Effectiveness Analysis of Adalimumab Versus Cyclosporine for Vogt-Koyanagi-Harada Disease: A Randomized Controlled Study.

IF 1.7 4区医学 Q3 OPHTHALMOLOGY

Current Eye Research Pub Date : 2024-10-01 Epub Date: 2024-05-23 DOI:10.1080/02713683.2024.2355659

Lingyu Dai, Zhenyu Zhong, Qiuying Wu, Yu Gao, Xiaorong Lu, Fuxiang Zhang, Chong Tang, Yao Wang, Chunjiang Zhou, Peizeng Yang

{"title":"Cost-Effectiveness Analysis of Adalimumab Versus Cyclosporine for Vogt-Koyanagi-Harada Disease: A Randomized Controlled Study.","authors":"Lingyu Dai, Zhenyu Zhong, Qiuying Wu, Yu Gao, Xiaorong Lu, Fuxiang Zhang, Chong Tang, Yao Wang, Chunjiang Zhou, Peizeng Yang","doi":"10.1080/02713683.2024.2355659","DOIUrl":null,"url":null,"abstract":"Purpose: To compare the 26-week cost-effectiveness of adalimumab-corticosteroids (ADA-CS) and cyclosporine-corticosteroids (CSA-CS) for Vogt-Koyanagi-Harada (VKH).Methods: A preplanned cost-effectiveness analysis based on the per-protocol population of a randomized-controlled trial. VKH subjects were randomized to receive either cyclosporine (100-200 mg daily) combined with corticosteroids or adalimumab (40 mg twice monthly) combined with corticosteroids. The primary outcome of this cost-effectiveness study was the incremental cost-effectiveness ratio (ICER). Costs and quality-adjusted life-years (QALYs) data were calculated by the medical records and health utility, respectively. Subgroup (early and late-phase VKH) analysis and sensitivity analyses were performed.Results: The ICER at 26 weeks was $62,425/QALY for the total participants. Compared to the CSA-CS group, costs in the ADA-CS group were more expensive (mean difference [ΔA-C]: $2,497) with more gains in QALYs (mean difference [ΔA-C]: 0.04). The probability of ADA-CS being cost-effective was 0.17 and 0.41 at willingness to pay (WTP) thresholds of $12,000/QALY and $36,000/QALY, respectively. Subgroup analysis and sensitivity analyses showed consistent findings with the primary analysis.Conclusions: Regardless of early or late-phase VKH, the CSA-CS strategy may be recommended as the preferred initial choice for the majority of VKH.","PeriodicalId":10782,"journal":{"name":"Current Eye Research","volume":" ","pages":"1080-1088"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Eye Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02713683.2024.2355659","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare the 26-week cost-effectiveness of adalimumab-corticosteroids (ADA-CS) and cyclosporine-corticosteroids (CSA-CS) for Vogt-Koyanagi-Harada (VKH).

Methods: A preplanned cost-effectiveness analysis based on the per-protocol population of a randomized-controlled trial. VKH subjects were randomized to receive either cyclosporine (100-200 mg daily) combined with corticosteroids or adalimumab (40 mg twice monthly) combined with corticosteroids. The primary outcome of this cost-effectiveness study was the incremental cost-effectiveness ratio (ICER). Costs and quality-adjusted life-years (QALYs) data were calculated by the medical records and health utility, respectively. Subgroup (early and late-phase VKH) analysis and sensitivity analyses were performed.

Results: The ICER at 26 weeks was $62,425/QALY for the total participants. Compared to the CSA-CS group, costs in the ADA-CS group were more expensive (mean difference [ΔA-C]: $2,497) with more gains in QALYs (mean difference [ΔA-C]: 0.04). The probability of ADA-CS being cost-effective was 0.17 and 0.41 at willingness to pay (WTP) thresholds of $12,000/QALY and $36,000/QALY, respectively. Subgroup analysis and sensitivity analyses showed consistent findings with the primary analysis.

Conclusions: Regardless of early or late-phase VKH, the CSA-CS strategy may be recommended as the preferred initial choice for the majority of VKH.

查看原文本刊更多论文

阿达木单抗与环孢素治疗Vogt-Koyanagi-Harada病的成本效益分析：随机对照研究

目的：比较阿达木单抗-皮质类固醇（ADA-CS）和环孢素-皮质类固醇（CSA-CS）治疗Vogt-Koyanagi-Harada（VKH）26周的成本效益：方法：根据随机对照试验的按方案人群进行预先计划的成本效益分析。VKH受试者被随机分配接受环孢素（每天100-200毫克）联合皮质类固醇激素或阿达木单抗（每月两次，每次40毫克）联合皮质类固醇激素治疗。这项成本效益研究的主要结果是增量成本效益比（ICER）。成本和质量调整生命年（QALYs）数据分别由医疗记录和健康效用计算得出。进行了亚组（早期和晚期 VKH）分析和敏感性分析：所有参与者在 26 周时的 ICER 为 62,425 美元/QALY。与 CSA-CS 组相比，ADA-CS 组的成本更昂贵（平均差异[ΔA-C]：2,497 美元），但 QALYs 收益更高（平均差异[ΔA-C]：0.04）。在支付意愿（WTP）阈值为 12,000 美元/QALY 和 36,000 美元/QALY 时，ADA-CS 具有成本效益的概率分别为 0.17 和 0.41。分组分析和敏感性分析结果与主要分析结果一致：无论 VKH 是早期还是晚期，CSA-CS 策略均可作为大多数 VKH 的首选初始方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Eye Research 医学-眼科学

CiteScore

4.60

自引率

0.00%

发文量

163

审稿时长

12 months

期刊介绍： The principal aim of Current Eye Research is to provide rapid publication of full papers, short communications and mini-reviews, all high quality. Current Eye Research publishes articles encompassing all the areas of eye research. Subject areas include the following: clinical research, anatomy, physiology, biophysics, biochemistry, pharmacology, developmental biology, microbiology and immunology.